Presentation (CTI)

OBJECTIVES: Major depressive disorder (MDD) is a chronic and recurrent psychiatric disorder associated with substantial disease burden, impaired quality of life, and productivity loss. Although antidepressants are widely used, many patients experience insufficient response, relapse, and adherence-related challenges, highlighting persistent unmet medical needs. Digital therapeutics have recently emerged as a novel non-pharmacological treatment option with potential advantages in accessibility and tolerability. CT-152 is an application-based digital therapeutic under development as an adjunctive treatment for patients with MDD who show insufficient response to antidepressants. This study evaluated the cost-effectiveness and value-based price of adjunctive CT-152 therapy compared with sham treatment from a Japanese societal perspective.
METHODS: A Markov model with a 48-week time horizon and 6-week cycle length was developed. Health states included no response, response, and remission. Initial transition probabilities were derived from the MIRAI trial, while long-term transition rates were obtained from published literature. Japanese data sources were used for utility values, healthcare costs, and productivity loss. Outcomes included total costs, quality-adjusted life years (QALYs), and value-based price estimates.
RESULTS: Compared with sham treatment, adjunctive CT-152 therapy reduced total societal costs by JPY 121,545 and increased QALYs by 0.033 over the 48-week analysis period, indicating that CT-152 was dominant, with lower costs and higher QALYs from a Japanese societal perspective. Based on the estimated health and societal benefits, the value-based price of 6 weeks of CT-152 treatment was estimated at JPY 286,085.
CONCLUSIONS: Based on currently available efficacy data from the MIRAI trial conducted in the United States, adjunctive CT-152 therapy may improve health outcomes while reducing societal costs compared with sham treatment in Japan. Further validation using efficacy data from ongoing Japanese clinical trials is warranted.